Methotrexate is the re-discovered drug for Crohn’s disease
Review articleGastroent Hepatol 2024; 78(1): 37–40. doi: 10.48095/ccgh202437
SummaryLiteraturepdf Milan LukášEfficacy and safety of switching from intravenous to subcutaneous CTP-13 treatment in IBD patients – a one-year retrospective study from large Slovak IBD centre
Original articleGastroent Hepatol 2024; 78(1): 31–36. doi: 10.48095/ccgh202431
SummaryLiteraturepdf Anna Gojdičová, Igor Šturdík, Jozef Tóth, Marek Gojdič, Zuzana Vrablicová, Iveta Čierna, Dagmar Szekyová, Alena Krónerová, Tibor HlavatýMirikizumab – the first anti-IL23 p19 antibody in ulcerative colitis therapy
Drug profileGastroent Hepatol 2024; 78(1): 27–30. doi: 10.48095/ccgh202427
Literaturepdf Milan LukášReduced urinary magnesium levels after ileocolic resection in patients with Crohn’s disease
Original articleGastroent Hepatol 2024; 78(1): 19–26. doi: 10.48095/ccgh202419
SummaryLiteraturepdf Vít Navrátil, Lumír Kunovský, Jan Křivinka, Jana Zapletalová, Přemysl Falt, Barbora PipekDoporučení Pracovní skupiny pro idiopatické střevní záněty pro diagnostiku Crohnovy choroby
GuidelinesGastroent Hepatol 2024; 78(1): 13–18. doi: 10.48095/ccgh202413
Literaturepdf Martin Bortlík, Dana Ďuricová, Pavel Drastich, Václav Mandys, Zuzana Šerclová, Naděžda Machková, Aleš Novotný, Karel Mareš, Jiří Stehlík, Milan LukášWhat will be your recommendation for therapy for severe ulcerative colitis?
QuizGastroent Hepatol 2024; 78(1): 11.
pdf Milan LukášPharmacological characteristics of subcutaneously administered monoclonal antibodies
Review articleGastroent Hepatol 2023; 77(6): 539–543. doi: 10.48095/ccgh2023539
SummaryLiteraturepdf Karel UrbánekUrolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
Review articleGastroent Hepatol 2023; 77(5): 437–446. doi: 10.48095/ccgh2023446
SummaryLiteraturepdf Vladimír Teplan, Radek Netušil, Milan Lukáš